Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients

Completed · Phase 1

Conditions studied: Lung Cancer

In brief

This study is to assess the safety and tolerability of Cediranib (RECENTIN™, AZD2171)in combination with etoposide and cisplatin (EP) as first line treatment for lung cancer patients with extensive stage or metastatic disease for whom EP would be a standard therapy.

Key facts

Study ID

NCT00621361

Run by

AstraZeneca

People needed

62

Starts

2008-02-01

Expected to finish

2012-02-01

Last updated by the study team

2012-12-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Cancer diagnosis and stage (histological or cytological confirmed extensive stage lung cancer, which EP would be considered a standard therapy, required at the time of diagnosis.)
• No prior chemotherapy or immunotherapy for advanced stage lung cancer (prior radiotherapy will be permitted if it is outside of the measurable field and greater than or equal to 2 weeks prior to entry to the study.)
• WHO performance status 0-2

You may not qualify if…

• Untreated unstable brain or meningeal metastases
• Patient with inappropriate laboratory tests values
• Inadequate bone marrow reserve.

Where it is running

• Research Site — Sacramento, California, United States
• Research Site — Denver, Colorado, United States
• Research Site — Kansas City, Kansas, United States
• Research Site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.